Redeye: LifeClean - Untapped potential
Redeye saw a lower sales development than we expected, while Opex was lower than estimates. With the current business climate in mind, the gross margin was in line and held up well. We adjust our estimates downward, primarily based on the slower sales development.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.